| Ticker |
IMVT
|
| CIK | 0001764013 |
| SIC | 2836 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Biological Products, Except Diagnostic Substances |
| Address | 320 WEST 37TH STREET, NEW YORK, NY, 10018 |
| Website | immunovant.com |
| Phone | 917-580-3099 |
| CEO | Peter Salzmann |
| Employees | 120 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold RatingImmunovant, Inc. (NASDAQ:IMVT) is one of the best momentum stocks to buy according to analysts. Truist lifted the price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $23 on May 22, maintaining a Hold rating on the shares. The firm told investors in a research note that it updated its model after the company reported fiscal […] This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 MillionStructure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last QuarterThis biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock SurgeThis biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline. Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock RallyVir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation. |
